More about Global Health Limited
Fundamentals for Global Health Limited
Regulatory Filings for Global Health Limited
The Renewable Success Story Beyond Solar
Startups Mint India’s New Billionaires
India's Biggest IPO Has a Bigger Meaning
From Watches to Wealth: Titan's New Empire
Fundamentals for Global Health Limited
Business Operations:
Sector: HealthcareIndustry: Medical Care Facilities
Global Health Limited engages in the provision of healthcare services in India. The company primarily offers treatments in the areas of digestive and hepatobiliary sciences, cardiac and cancer care, neurosciences, gastrosciences, musculoskeletal disorders and orthopaedics, renal care, liver transplant, lung transplant, bone marrow transplant, chest surgery, gynaecology and gynaeoncology, paediatric care, obstetrics, plastic, aesthetic and reconstructive surgery, ENT, head and neck surgery, internal medicine, respiratory and sleep medicine, peripheral vascular and endovascular sciences, endocrinology and diabetes, rheumatology and immunology, radiology and imaging, ophthalmology, critical care, dermatology, dentistry, ayurveda, and dietetics and nutrition. It also offers lab tests and diagnostics, homecare and elder care services, telemedicine and air ambulance services, blood bank and e-ICU services, and health plans, as well as operates pharmacies. The company operates a network of hospitals under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in New Delhi, India.
Revenue projections:
Global Health Limited's projected revenue decline from last year is likely to make investors cautious. Lower revenues often hurt a company's bottom line, leading investors to be concerned about the company's ability to maintain profitability and deliver strong financial results in the future.
Financial Ratios:
| currentRatio | 2.67100 |
|---|---|
| forwardPE | 40.66477 |
| debtToEquity | 29.86900 |
| earningsGrowth | 0.42000 |
| revenueGrowth | 0.24500 |
| grossMargins | 0.52545 |
| operatingMargins | 0.15292 |
| trailingEps | 20.70000 |
| forwardEps | 32.27364 |
With a current ratio of 2.671, Global Health Limited has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that Global Health Limited is in a strong position to meet its immediate financial obligations without difficulty.
Global Health Limited's low Debt-to-Equity ratio reflects that the company isn't heavily reliant on debt, reducing financial risk. This conservative approach suggests Global Health Limited maintains a stable financial foundation, with greater flexibility to manage future growth or challenges without over-leverage concerns.
MEDANTA's positive earnings and revenue growth point to business expansion on the horizon. The company is positioned for continued success, with increasing profits and revenue growth highlighting a strong path forward for future growth.
MEDANTA's forward EPS exceeding its trailing EPS means that the company is expected to increase profitability in the current financial year. This reflects improved earnings potential, signaling that MEDANTA is likely to outperform its previous year's financial performance.
Price projections:
The steady upward revision of MEDANTA's price projections indicates growing confidence in the company's performance. Analysts are becoming increasingly optimistic about MEDANTA's future prospects and potential for growth.
Recommendation changes over time:
With analysts showing a buy bias for MEDANTA, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning MEDANTA as a safe and profitable place for investors to allocate their funds and seek growth.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
SEBI's New Gateway Is Rewiring Foreign Investment in India
Why Japan Backs India’s Truckers
India's $69B Eurasian Trade Power Play